<DOC>
	<DOCNO>NCT00334178</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Laxymig® ER compare placebo prophylactic monotherapy treatment migraine headache .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Laxymig® Prophylactic Treatment Patients With Migraine</brief_title>
	<detailed_description>The purpose study evaluate efficacy safety Laxymig® ER compare placebo prophylactic monotherapy treatment migraine headache . Four week baseline , follow 12 week treatment phase . Subjects migraine record diary card re-evaluated investigator . Subject visit every 4-week ( +/- 7 day ) .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Migraine without Aura</mesh_term>
	<mesh_term>Migraine Aura</mesh_term>
	<criteria>Clinical diagnosis migraine without aura ( typical aura migraine headache ) Subjects average two migraine frequency per month 3 month screen Female subject pregnant , lactate Chronic daily headache Previous treatment three migraine prophylaxis medication fail Subjects hepatic disease whose liver enzymes 2 time upper limit reference significant dysfunction Coexisting medical , neurological , psychiatric disorder may hinder study accord investigator 's judgment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Migraine prophylaxis</keyword>
</DOC>